Right now, the only available treatment forceliac diseaseis agluten-free diet.
But that may soon be changing.
Each has a different approach and mechanism of action (MOA).
Cultura RM Exclusive / Matt Lincoln / Getty Images
The most promising candidates in the drug pipeline include the following.
The results of phase II clinical trial were promising and demonstrated that the drug was both safe and tolerable.
Some dietary restriction would still be needed.
The U.S. Food and Drug Administration (FDA) has fast-tracked INN-202.
Phase III clinical trials are currently underway.
Results of the trial may be available sometime in mid- to late-2022.
BL-7010
BL-7010 offers an entirely different approach to treating celiac disease.
By achieving this, the immune system is less able to trigger an autoimmune response.
The bound gluten and drug would then be expelled from the body in the stool.
In the end, any candidate would need to fulfill three promises if they are to be considered viable.
So there still remains a lot to be answered.
U.S. National Library of Medicine.Safety and systemic exposure study of BL-7010 in well-controlled celiac patients.
